OTIC - Otonomy reports clinical benefit for hearing loss therapy in mid-stage trial

Announcing topline data from a Phase 2a clinical trial involving patients with hearing loss, the clinical-stage biopharma company, Otonomy (NASDAQ:OTIC), said on Wednesday that a single injection of OTO-413 led to a “clinically meaningful treatment benefit versus placebo” across several measures. The company has used multiple speech-in-noise (SIN) hearing tests as well as the Patient Global Impression of Change (PGIC) to measure the clinical response at consecutive time points (Days 57 and 85). Out of 30 evaluable patients, 20 were treated with OTO-413, while 10 received the placebo. On both Days, 40% (8 of 20) of OTO-413 subjects showed a clinically meaningful improvement on at least one of the three SIN tests compared to 20% (2 out of 10) for placebo. Meanwhile, 15% (3 of 20) OTO-413-treated patients indicated a clinically-meaningful improvement by two or more different SIN tests on both days compared to none in the placebo arm. In

For further details see:

Otonomy reports clinical benefit for hearing loss therapy in mid-stage trial